{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T03:09:48Z","timestamp":1788923388822,"version":"build-2803163510"},"reference-count":142,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bcp.2026.118199","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T23:30:01Z","timestamp":1782516601000},"page":"118199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Targeting Cav2.2 channels for pain management: challenges, innovations, and future perspectives"],"prefix":"10.1016","volume":"252","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0972-9524","authenticated-orcid":false,"given":"Fangla","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwei","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlong","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeru","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2026.118199_b0005","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/S0140-6736(21)00393-7","article-title":"Chronic pain: an update on burden, best practices, and new advances","volume":"397","author":"Cohen","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2026.118199_b0010","doi-asserted-by":"crossref","unstructured":"N. The Lancet, Rethinking chronic pain, Lancet 397 (2021) 2023. 10.1016\/S0140-6736(21)01194-6.","DOI":"10.1016\/S0140-6736(21)01194-6"},{"key":"10.1016\/j.bcp.2026.118199_b0015","doi-asserted-by":"crossref","first-page":"379","DOI":"10.15585\/mmwr.mm7215a1","article-title":"Chronic pain among adults - united states, 2019-2021","volume":"72","author":"Rikard","year":"2023","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"10.1016\/j.bcp.2026.118199_b0020","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3322\/caac.21823","article-title":"Opioid analgesics for nociceptive cancer pain: a comprehensive review, CA","volume":"74","author":"Abdel Shaheed","year":"2024","journal-title":"Cancer J. Clin."},{"key":"10.1016\/j.bcp.2026.118199_b0025","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.pain.2006.10.019","article-title":"Voltage-gated calcium channels and pain","volume":"126","author":"Cao","year":"2006","journal-title":"Pain"},{"key":"10.1016\/j.bcp.2026.118199_b0030","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00424-022-02666-y","article-title":"Voltage-dependent CaV3.2 and CaV2.2 channels in nociceptive pathways","volume":"474","author":"Hoppanova","year":"2022","journal-title":"Pfl\u00fcg Arch. - Eur. J. Physiol."},{"key":"10.1016\/j.bcp.2026.118199_b0035","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/nrd2487","article-title":"Drug development from marine natural products","volume":"8","author":"Molinski","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2026.118199_b0040","doi-asserted-by":"crossref","unstructured":"K.A. Lyseng-Williamson, C. Perry, Ziconotide, CNS Drugs 20 (2006) 331\u2013338; discussion 339-341. https:\/\/doi.org\/10.2165\/00023210-200620040-00007.","DOI":"10.2165\/00023210-200620040-00007"},{"key":"10.1016\/j.bcp.2026.118199_b0045","article-title":"A comprehensive review on ziconotide","volume":"10","author":"Lin","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.bcp.2026.118199_b0050","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1146\/annurev.cellbio.16.1.521","article-title":"Structure and regulation of voltage-gated Ca2+ channels","volume":"16","author":"Catterall","year":"2000","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"10.1016\/j.bcp.2026.118199_b0055","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/pr.114.009654","article-title":"The physiology, pathology, and pharmacology of voltage-gated calcium channels and their future therapeutic potential","volume":"67","author":"Zamponi","year":"2015","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bcp.2026.118199_b0060","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.bbi.2018.04.016","article-title":"Upregulation of N-type calcium channels in the soma of uninjured dorsal root ganglion neurons contributes to neuropathic pain by increasing neuronal excitability following peripheral nerve injury","volume":"71","author":"Yang","year":"2018","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bcp.2026.118199_b0065","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.bcp.2005.04.035","article-title":"Use-dependent blockade of Cav2.2 voltage-gated calcium channels for neuropathic pain","volume":"70","author":"Winquist","year":"2005","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118199_b0070","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1021\/bi00382a004","article-title":"Neuronal calcium channel antagonists. Discrimination between calcium channel subtypes using omega-conotoxin from conus magus venom","volume":"26","author":"Olivera","year":"1987","journal-title":"Biochemistry"},{"key":"10.1016\/j.bcp.2026.118199_b0075","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1385\/MN:26:1:021","article-title":"Functional diversity in neuronal voltage-gated calcium channels by alternative splicing of Ca(v)alpha1","volume":"26","author":"Lipscombe","year":"2002","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.bcp.2026.118199_b0080","doi-asserted-by":"crossref","first-page":"5369","DOI":"10.1113\/JP272262","article-title":"Voltage-gated calcium channels and their auxiliary subunits: physiology and pathophysiology and pharmacology","volume":"594","author":"Dolphin","year":"2016","journal-title":"J. Physiol."},{"key":"10.1016\/j.bcp.2026.118199_b0085","doi-asserted-by":"crossref","first-page":"14950","DOI":"10.1073\/pnas.1005940107","article-title":"Quantitative proteomics of the Cav2 channel nano-environments in the mammalian brain","volume":"107","author":"M\u00fcller","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bcp.2026.118199_b0090","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41586-021-03699-6","article-title":"Structure of human Cav2.2 channel blocked by the painkiller ziconotide","volume":"596","author":"Gao","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118199_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109931","article-title":"Closed-state inactivation and pore-blocker modulation mechanisms of human CaV2.2","volume":"37","author":"Dong","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.bcp.2026.118199_b0100","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/385446a0","article-title":"Direct binding of G-protein betagamma complex to voltage-dependent calcium channels","volume":"385","author":"De Waard","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118199_b0105","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adp6665","article-title":"Voltage-dependent G-protein regulation of CaV2.2 (N-type) channels","volume":"10","author":"Nilsson","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bcp.2026.118199_b0110","first-page":"302","article-title":"A proteomic screen for presynaptic terminal N-type calcium channel (CaV2.2) binding partners","volume":"40","author":"Khanna","year":"2007","journal-title":"J. Biochem. Mol. Biol."},{"key":"10.1016\/j.bcp.2026.118199_b0115","doi-asserted-by":"crossref","first-page":"E12043","DOI":"10.1073\/pnas.1811212115","article-title":"Ablation of \u03b12\u03b4-1 inhibits cell-surface trafficking of endogenous N-type calcium channels in the pain pathway in vivo","volume":"115","author":"Nieto-Rostro","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bcp.2026.118199_b0120","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41594-023-00951-7","article-title":"Structural basis for CaV\u03b12\u03b4:gabapentin binding","volume":"30","author":"Chen","year":"2023","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.bcp.2026.118199_b0125","doi-asserted-by":"crossref","first-page":"6984","DOI":"10.1523\/JNEUROSCI.1137-05.2005","article-title":"Interaction via a key tryptophan in the I-II linker of N-type calcium channels is required for beta1 but not for palmitoylated beta2, implicating an additional binding site in the regulation of channel voltage-dependent properties","volume":"25","author":"Leroy","year":"2005","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"10.1016\/j.bcp.2026.118199_b0130","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2305215120","article-title":"A peptidomimetic modulator of the CaV2.2 N-type calcium channel for chronic pain","volume":"120","author":"Gomez","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bcp.2026.118199_b0135","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.7150\/ijbs.110504","article-title":"Regulatory action of calcium and calcium channels in pain pathways","volume":"21","author":"Zhang","year":"2025","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.bcp.2026.118199_b0140","first-page":"1629","article-title":"Regulation of Ca(V)2 calcium channels by G protein coupled receptors","volume":"2013","author":"Zamponi","year":"1828","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bcp.2026.118199_b0145","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1085\/jgp.201311153","article-title":"Calmodulin regulation (calmodulation) of voltage-gated calcium channels","volume":"143","author":"Ben-Johny","year":"2014","journal-title":"J. Gen. Physiol."},{"key":"10.1016\/j.bcp.2026.118199_b0150","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2174\/157340606778250216","article-title":"N-type calcium channel blockers: novel therapeutics for the treatment of pain","volume":"2","author":"Schroeder","year":"2006","journal-title":"Med. Chem."},{"key":"10.1016\/j.bcp.2026.118199_b0155","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejphar.2015.12.031","article-title":"Injury-specific functional alteration of N-type voltage-gated calcium channels in synaptic transmission of primary afferent C-fibers in the rat spinal superficial dorsal horn","volume":"772","author":"Takasu","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118199_b0160","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3390\/life15060888","article-title":"Voltage-gated ion channels in neuropathic pain signaling","volume":"15","author":"Felix","year":"2025","journal-title":"Life"},{"key":"10.1016\/j.bcp.2026.118199_b0165","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/340153a0","article-title":"Neurotransmitter inhibition of neuronal calcium currents by changes in channel voltage dependence","volume":"340","author":"Bean","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118199_b0170","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1073\/pnas.94.4.1512","article-title":"Molecular determinants of inactivation and G protein modulation in the intracellular loop connecting domains I and II of the calcium channel alpha1A subunit","volume":"94","author":"Herlitze","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bcp.2026.118199_b0175","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4149\/gpb_2019004","article-title":"Structure, function and regulation of CaV2.2 N-type calcium channels","volume":"38","author":"Jurkovicova-Tarabova","year":"2019","journal-title":"Gen. Physiol. Biophys."},{"key":"10.1016\/j.bcp.2026.118199_b0180","doi-asserted-by":"crossref","first-page":"5707","DOI":"10.1073\/pnas.1616394114","article-title":"Identification of Cav2-PKC\u03b2 and Cav2-NOS1 complexes as entities for ultrafast electrochemical coupling","volume":"114","author":"Constantin","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bcp.2026.118199_b0185","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1097\/j.pain.0000000000002846","article-title":"Nerve injury increases native Ca V 2.2 trafficking in dorsal root ganglion mechanoreceptors","volume":"164","author":"Nieto-Rostro","year":"2023","journal-title":"Pain"},{"key":"10.1016\/j.bcp.2026.118199_b0190","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.3390\/cells14141114","article-title":"Therapeutic potential of calcium channel blockers in neuropsychiatric, endocrine and pain disorders","volume":"14","author":"Manzar","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.bcp.2026.118199_b0195","doi-asserted-by":"crossref","first-page":"5285","DOI":"10.1074\/jbc.M113.523639","article-title":"Ankyrin-B regulates Cav2.1 and Cav2.2 channel expression and targeting","volume":"289","author":"Kline","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2026.118199_b0200","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1468-2982.2004.00656.x","article-title":"Effects of N-, P\/Q- and L-type calcium channel blockers on nociceptive neurones of the trigeminal nucleus with input from the dura","volume":"24","author":"Ebersberger","year":"2004","journal-title":"Cephalalgia Int. J. Headache"},{"key":"10.1016\/j.bcp.2026.118199_b0205","doi-asserted-by":"crossref","first-page":"5333","DOI":"10.1113\/JP283600","article-title":"Involvement of CaV 2.2 channels and \u03b12 \u03b4-1 in homeostatic synaptic plasticity in cultured hippocampal neurons","volume":"600","author":"Pilch","year":"2022","journal-title":"J. Physiol."},{"key":"10.1016\/j.bcp.2026.118199_b0210","first-page":"1459","article-title":"Protofibrillar amyloid beta modulation of recombinant hCaV2.2 (N-Type) voltage-gated channels","volume":"15","author":"Kaisis","year":"2022","journal-title":"Pharm. Basel Switz."},{"key":"10.1016\/j.bcp.2026.118199_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111873","article-title":"Multi-modal characterization and simulation of human epileptic circuitry","volume":"41","author":"Buchin","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.bcp.2026.118199_b0220","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1002\/1873-3468.13853","article-title":"Knockdown of microglial Cav2.2 N-type voltage-dependent Ca2+ channel ameliorates behavioral deficits in a mouse model of Parkinson\u2019s disease","volume":"594","author":"Saegusa","year":"2020","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bcp.2026.118199_b0225","doi-asserted-by":"crossref","unstructured":"T. G, B. A, F. C, B. S, P. F, C. G, de I. A, C. P, P. B, C. E, D.M. S, M. A, C. V, \u03b1-synuclein oligomers slow down action potential firing and enhance dopamine release by increasing Cav2.2 currents in midbrain dopaminergic neurons, J. Physiol. 604 (2026). https:\/\/doi.org\/10.1113\/JP288914.","DOI":"10.1113\/JP288914"},{"key":"10.1016\/j.bcp.2026.118199_b0230","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41531-025-01110-z","article-title":"N-type Ca2+ channels mediate the stimuli-dependent \u03b1-synuclein secretion in mouse striatum","volume":"11","author":"Leandrou","year":"2025","journal-title":"Npj Park. Dis."},{"key":"10.1016\/j.bcp.2026.118199_b0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2017.03.015","article-title":"N-type Ca2+ channels are affected by full-length mutant huntingtin expression in a mouse model of Huntington\u2019s disease","volume":"55","author":"Silva","year":"2017","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.bcp.2026.118199_b0240","doi-asserted-by":"crossref","first-page":"27192","DOI":"10.1038\/srep27192","article-title":"Ablation of the N-type calcium channel ameliorates diabetic nephropathy with improved glycemic control and reduced blood pressure","volume":"6","author":"Ohno","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2026.118199_b0245","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0014-2999(01)01521-7","article-title":"Antisympathetic and hemodynamic property of a dual L\/N-type Ca(2+) channel blocker cilnidipine in rats","volume":"434","author":"Takahara","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118199_b0250","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1038\/sj.bjp.0703701","article-title":"Cardiovascular and autonomic effects of omega-conotoxins MVIIA and CVID in conscious rabbits and isolated tissue assays","volume":"131","author":"Wright","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118199_b0255","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/00005344-199709000-00019","article-title":"Sympatholysis after neuron-specific, N-type, voltage-sensitive calcium channel blockade: first demonstration of N-channel function in humans","volume":"30","author":"McGuire","year":"1997","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118199_b0260","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/cvr\/cvaa018","article-title":"Inhibition of N-type calcium channels in cardiac sympathetic neurons attenuates ventricular arrhythmogenesis in heart failure","volume":"117","author":"Zhang","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.bcp.2026.118199_b0265","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1093\/pm\/pnaa251","article-title":"Ziconotide for management of cancer pain refractory to pharmacotherapy: an update","volume":"21","author":"Banik","year":"2020","journal-title":"Pain Med."},{"key":"10.1016\/j.bcp.2026.118199_b0270","article-title":"Intrathecal therapy: what has changed with the introduction of ziconotide","volume":"9","author":"Hg","year":"2009","journal-title":"Pain Pract. Off. J. World Inst. Pain"},{"key":"10.1016\/j.bcp.2026.118199_b0275","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1007\/s11255-022-03183-8","article-title":"N-type calcium channel and renal injury","volume":"54","author":"Bai","year":"2022","journal-title":"Int. Urol. Nephrol."},{"key":"10.1016\/j.bcp.2026.118199_b0280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0223496","article-title":"Attenuation of renal fibrosis after unilateral ureteral obstruction in mice lacking the N-type calcium channel","volume":"14","author":"Mishima","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2026.118199_b0285","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0304-3959(99)00255-9","article-title":"Ziconotide for the treatment of severe spasticity after spinal cord injury","volume":"85","author":"Ridgeway","year":"2000","journal-title":"Pain"},{"key":"10.1016\/j.bcp.2026.118199_b0290","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2024.1412855","article-title":"Ziconotide and psychosis: from a case report to a scoping review","volume":"17","author":"Peraire","year":"2024","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.bcp.2026.118199_b0295","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/pm\/pny132","article-title":"Intrathecal therapy for chronic pain: a review of morphine and ziconotide as firstline options","volume":"20","author":"Deer","year":"2019","journal-title":"Pain Med."},{"key":"10.1016\/j.bcp.2026.118199_b0300","unstructured":"P. Anand, Tailored delivery of analgesic ziconotide across a blood brain barrier model using viral nanocontainers, Sci. Rep. (n.d.)."},{"key":"10.1016\/j.bcp.2026.118199_b0305","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3390\/md21040229","article-title":"Self-assembly nanostructure of myristoylated \u03c9-conotoxin MVIIA increases the duration of efficacy and reduces side effects","volume":"21","author":"Ding","year":"2023","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.bcp.2026.118199_b0310","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3390\/md17050286","article-title":"TAT-modified \u03c9-conotoxin MVIIA for crossing the blood-brain barrier","volume":"17","author":"Yu","year":"2019","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.bcp.2026.118199_b0315","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jconrel.2015.12.044","article-title":"Delivery of ziconotide to cerebrospinal fluid via intranasal pathway for the treatment of chronic pain","volume":"224","author":"Manda","year":"2016","journal-title":"J. Control. Release off. J. Control. Release Soc."},{"key":"10.1016\/j.bcp.2026.118199_b0320","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jconrel.2023.03.007","article-title":"Microneedle-mediated delivery of Ziconotide-loaded liposomes fused with exosomes for analgesia","volume":"356","author":"Song","year":"2023","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.bcp.2026.118199_b0325","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jconrel.2022.02.011","article-title":"Challenges in delivering therapeutic peptides and proteins: a silk-based solution","volume":"345","author":"Wu","year":"2022","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.bcp.2026.118199_b0330","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1016\/j.apsb.2021.03.001","article-title":"A novel \u03c9-conotoxin Bu8 inhibiting N-type voltage-gated calcium channels displays potent analgesic activity","volume":"11","author":"Chen","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bcp.2026.118199_b0335","article-title":"A chemoenzymatic approach to produce a cyclic analogue of the analgesic drug MVIIA (ziconotide)","volume":"62","author":"Zhou","year":"2023","journal-title":"Angew. Chem."},{"key":"10.1016\/j.bcp.2026.118199_b0340","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1111\/bph.16309","article-title":"An orally available Cav2.2 calcium channel inhibitor for the treatment of neuropathic pain","volume":"181","author":"Kutzsche","year":"2024","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118199_b0345","doi-asserted-by":"crossref","first-page":"9847","DOI":"10.1021\/jm301056k","article-title":"Aminopiperidine sulfonamide Cav2.2 channel inhibitors for the treatment of chronic pain","volume":"55","author":"Shao","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118199_b0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108194","article-title":"Coronaridine congeners decrease neuropathic pain in mice and inhibit \u03b19\u03b110 nicotinic acetylcholine receptors and CaV2.2 channels","volume":"175","author":"Arias","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2026.118199_b0355","doi-asserted-by":"crossref","DOI":"10.1172\/JCI177429","article-title":"C2230, a preferential use- and state-dependent CaV2.2 channel blocker, mitigates pain behaviors across multiple pain models","volume":"135","author":"Tang","year":"2025","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2026.118199_b0360","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1021\/acs.jmedchem.5c02649","article-title":"Design and characterization of a dual COX-2\/CaV2.2 inhibitor with potent analgesic activity","volume":"69","author":"Qiu","year":"2026","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118199_b0365","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1097\/j.pain.0000000000002344","article-title":"Conditional knockout of CRMP2 in neurons, but not astrocytes, disrupts spinal nociceptive neurotransmission to control the initiation and maintenance of chronic neuropathic pain","volume":"163","author":"Boinon","year":"2022","journal-title":"Pain"},{"key":"10.1016\/j.bcp.2026.118199_b0370","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nm.2345","article-title":"Suppression of inflammatory and neuropathic pain by uncoupling CRMP-2 from the presynaptic Ca2+ channel complex","volume":"17","author":"Brittain","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2026.118199_b0375","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1097\/j.pain.0000000000001026","article-title":"Dissecting the role of the CRMP2-neurofibromin complex on pain behaviors","volume":"158","author":"Moutal","year":"2017","journal-title":"Pain"},{"key":"10.1016\/j.bcp.2026.118199_b0380","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1111\/bph.13737","article-title":"Homology-guided mutational analysis reveals the functional requirements for antinociceptive specificity of collapsin response mediator protein 2-derived peptides","volume":"175","author":"Moutal","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118199_b0385","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1097\/j.pain.0000000000000628","article-title":"Sustained relief of ongoing experimental neuropathic pain by a CRMP2 peptide aptamer with low abuse potential","volume":"157","author":"Xie","year":"2016","journal-title":"Pain"},{"key":"10.1016\/j.bcp.2026.118199_b0390","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1097\/j.pain.0000000000000147","article-title":"A membrane-delimited N-myristoylated CRMP2 peptide aptamer inhibits CaV2.2 trafficking and reverses inflammatory and postoperative pain behaviors","volume":"156","author":"Fran\u00e7ois-Moutal","year":"2015","journal-title":"Pain"},{"key":"10.1016\/j.bcp.2026.118199_b0395","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.3390\/ph15101283","article-title":"Strategies for improving peptide stability and delivery","volume":"15","author":"Al Musaimi","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bcp.2026.118199_b0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpain.2024.104664","article-title":"Uncoupling the CRMP2-CaV2.2 interaction reduces pain-like behavior in a preclinical joint-pain model","volume":"25","author":"Allen","year":"2024","journal-title":"J. Pain"},{"key":"10.1016\/j.bcp.2026.118199_b0405","article-title":"R and S enantiomers of CBD3063, a CaV2.2 N-type calcium channel modulator, alleviate capsaicin-induced inflammatory pain","volume":"18","author":"Loya-L\u00f3pez","year":"2025","journal-title":"Neurobiol. Pain Camb. Mass"},{"key":"10.1016\/j.bcp.2026.118199_b0410","doi-asserted-by":"crossref","first-page":"13037","DOI":"10.1021\/acsnano.4c17325","article-title":"Targeted ganglion delivery of CaV2.2-mediated peptide by DNA nanoflowers for relieving myocardial infarction and neuropathic pain","volume":"19","author":"Qiao","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.bcp.2026.118199_b0415","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1097\/j.pain.0000000000000555","article-title":"(S)-lacosamide inhibition of CRMP2 phosphorylation reduces postoperative and neuropathic pain behaviors through distinct classes of sensory neurons identified by constellation pharmacology","volume":"157","author":"Moutal","year":"2016","journal-title":"Pain"},{"key":"10.1016\/j.bcp.2026.118199_b0420","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13041-020-00633-1","article-title":"Differential expression of Cdk5-phosphorylated CRMP2 following a spared nerve injury","volume":"13","author":"Moutal","year":"2020","journal-title":"Mol. Brain"},{"key":"10.1016\/j.bcp.2026.118199_b0425","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1097\/j.pain.0000000000001002","article-title":"CRISPR\/Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1-related pain that is reversed by (S)-lacosamide","volume":"158","author":"Moutal","year":"2017","journal-title":"Pain"},{"key":"10.1016\/j.bcp.2026.118199_b0430","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1460-9568.2007.05680.x","article-title":"The presynaptic CaV2.2 channel-transmitter release site core complex","volume":"26","author":"Khanna","year":"2007","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.bcp.2026.118199_b0435","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.apsb.2023.01.021","article-title":"Rhodojaponin VI indirectly targets Cav2.2 channels via N-ethylmaleimide-sensitive fusion protein to alleviate neuropathic pain","volume":"13","author":"Chen","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bcp.2026.118199_b0440","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1523\/JNEUROSCI.0356-09.2009","article-title":"The increased trafficking of the calcium channel subunit alpha2delta-1 to presynaptic terminals in neuropathic pain is inhibited by the alpha2delta ligand pregabalin","volume":"29","author":"Bauer","year":"2009","journal-title":"J. Neurosci. Off. J Soc. Neurosci."},{"key":"10.1016\/j.bcp.2026.118199_b0445","doi-asserted-by":"crossref","first-page":"8494","DOI":"10.1523\/JNEUROSCI.2982-04.2004","article-title":"Spinal dorsal horn calcium channel alpha2delta-1 subunit upregulation contributes to peripheral nerve injury-induced tactile allodynia","volume":"24","author":"Li","year":"2004","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"10.1016\/j.bcp.2026.118199_b0450","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1080\/14737175.2016.1202764","article-title":"Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use","volume":"16","author":"Calandre","year":"2016","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.bcp.2026.118199_b0455","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.coph.2005.11.003","article-title":"The mechanisms of action of gabapentin and pregabalin","volume":"6","author":"Sills","year":"2006","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118199_b0460","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1073\/pnas.0708930105","article-title":"Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin","volume":"105","author":"Hendrich","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bcp.2026.118199_b0465","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3344\/kjp.2020.33.1.3","article-title":"Pregabalin and gabapentin in neuropathic pain management after spinal cord injury: a systematic review and meta-analysis","volume":"33","author":"Davari","year":"2020","journal-title":"Korean J. Pain"},{"key":"10.1016\/j.bcp.2026.118199_b0470","article-title":"Pregabalin vs. gabapentin in the treatment of neuropathic pain: a comprehensive systematic review and meta-analysis of effectiveness and safety","volume":"5","author":"Mayoral","year":"2024","journal-title":"Front. Pain Res."},{"key":"10.1016\/j.bcp.2026.118199_b0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116472","article-title":"A next generation peripherally restricted Cav\u03b12\u03b4-1 ligand with inhibitory action on Cav2.2 channels and utility in neuropathic pain","volume":"174","author":"Kricek","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bcp.2026.118199_b0480","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1491570","article-title":"Mirogabalin as a novel calcium channel \u03b12\u03b4 ligand for the treatment of neuropathic pain: a review of clinical update","volume":"15","author":"Yang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118199_b0485","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3390\/ph14020112","article-title":"Mirogabalin-a novel selective ligand for the \u03b12\u03b4 calcium channel subunit","volume":"14","author":"Zaj\u0105czkowska","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bcp.2026.118199_b0490","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13041-024-01129-y","article-title":"Determinants of interactions of a novel next-generation gabapentinoid NVA1309 and mirogabalin with the Cav\u03b12\u03b4-1 subunit","volume":"17","author":"Souza","year":"2024","journal-title":"Mol. Brain"},{"key":"10.1016\/j.bcp.2026.118199_b0495","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1097\/j.pain.0000000000001524","article-title":"Targeting the CaV\u03b1-CaV\u03b2 interaction yields an antagonist of the N-type CaV2.2 channel with broad antinociceptive efficacy","volume":"160","author":"Khanna","year":"2019","journal-title":"Pain"},{"key":"10.1016\/j.bcp.2026.118199_b0500","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1080\/19336950.2020.1863595","article-title":"Comparison of quinazoline and benzoylpyrazoline chemotypes targeting the CaV\u03b1-\u03b2 interaction as antagonists of the N-type CaV2.2 channel","volume":"15","author":"Ran","year":"2021","journal-title":"Channels"},{"key":"10.1016\/j.bcp.2026.118199_b0505","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nrn3311","article-title":"Calcium channel auxiliary \u03b12\u03b4 and \u03b2 subunits: trafficking and one step beyond","volume":"13","author":"Dolphin","year":"2012","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.bcp.2026.118199_b0510","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nature12725","article-title":"Structural mechanism of ligand activation in human GABA(B) receptor","volume":"504","author":"Geng","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118199_b0515","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1124\/molpharm.122.000543","article-title":"Analgesic \u03b1-conotoxin binding site on the human GABAB receptor","volume":"102","author":"Bony","year":"2022","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118199_b0520","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1038\/s44319-024-00147-0","article-title":"Synaptotagmin-11 facilitates assembly of a presynaptic signaling complex in post-golgi cargo vesicles","volume":"25","author":"Trov\u00f2","year":"2024","journal-title":"EMBO Rep."},{"key":"10.1016\/j.bcp.2026.118199_b0525","doi-asserted-by":"crossref","first-page":"11510","DOI":"10.1021\/acs.chemrev.9b00207","article-title":"Conotoxins: chemistry and biology","volume":"119","author":"Jin","year":"2019","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bcp.2026.118199_b0530","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2021.765541","article-title":"Interaction of \u03b19\u03b110 nicotinic receptors with peptides and proteins from animal venoms","volume":"15","author":"Tsetlin","year":"2021","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.bcp.2026.118199_b0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.108017","article-title":"Molecular determinants of the selectivity and potency of \u03b1-conotoxin Vc1.1 for human nicotinic acetylcholine receptors","volume":"301","author":"Tae","year":"2025","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2026.118199_b0540","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1111\/j.1471-4159.2012.07867.x","article-title":"Molecular basis for the differential sensitivity of rat and human \u03b19\u03b110 nAChRs to \u03b1-conotoxin RgIA","volume":"122","author":"Azam","year":"2012","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bcp.2026.118199_b0545","doi-asserted-by":"crossref","first-page":"10943","DOI":"10.1523\/JNEUROSCI.3594-08.2008","article-title":"Analgesic alpha-conotoxins Vc1.1 and Rg1A inhibit N-type calcium channels in rat sensory neurons via GABAB receptor activation","volume":"28","author":"Callaghan","year":"2008","journal-title":"J. Neurosci. Off. J Soc. Neurosci."},{"key":"10.1016\/j.bcp.2026.118199_b0550","doi-asserted-by":"crossref","first-page":"10198","DOI":"10.1021\/acs.jmedchem.8b01343","article-title":"Targeting of N-type calcium channels via GABAB-receptor activation by \u03b1-conotoxin Vc1.1 variants displaying improved analgesic activity","volume":"61","author":"Cai","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118199_b0555","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1021\/acs.jmedchem.0c02151","article-title":"Alkyne-bridged \u03b1-conotoxin Vc1.1 potently reverses mechanical allodynia in neuropathic pain models","volume":"64","author":"Belgi","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118199_b0560","doi-asserted-by":"crossref","first-page":"750","DOI":"10.3390\/md20120750","article-title":"A single amino acid replacement boosts the analgesic activity of \u03b1-conotoxin AuIB through the inhibition of the GABABR-coupled N-type calcium channel","volume":"20","author":"Wei","year":"2022","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.bcp.2026.118199_b0565","doi-asserted-by":"crossref","first-page":"E4026","DOI":"10.1073\/pnas.1503617112","article-title":"Cloning, synthesis, and characterization of \u03b1O-conotoxin GeXIVA, a potent \u03b19\u03b110 nicotinic acetylcholine receptor antagonist","volume":"112","author":"Luo","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bcp.2026.118199_b0570","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/jnc.15535","article-title":"\u0251O-conotoxin GeXIVA isomers modulate N-type calcium (CaV 2.2) channels and inwardly-rectifying potassium (GIRK) channels via GABAB receptor activation","volume":"160","author":"Yousuf","year":"2022","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bcp.2026.118199_b0575","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3390\/md16040112","article-title":"Cloning, synthesis and functional characterization of a novel \u03b1-conotoxin Lt1.3","volume":"16","author":"Chen","year":"2018","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.bcp.2026.118199_b0580","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1021\/acs.jmedchem.3c00979","article-title":"Dual antagonism of \u03b19\u03b110 nAChR and GABAB receptor-coupled CaV2.2 channels by an analgesic \u03b1O-conotoxin analogue","volume":"67","author":"Li","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118199_b0585","doi-asserted-by":"crossref","first-page":"18400","DOI":"10.1021\/acs.jmedchem.4c01758","article-title":"N-terminal capping of the \u03b1O-conotoxin analogue GeX-2 improves the serum stability and selectivity toward the human \u03b19\u03b110 nicotinic acetylcholine receptor","volume":"67","author":"Li","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118199_b0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106715","article-title":"Nicotinic acetylcholine receptors: therapeutic targets for novel ligands to treat pain and inflammation","volume":"190","author":"Hone","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2026.118199_b0595","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1080\/10717544.2022.2089297","article-title":"Preparation of uniform-sized GeXIVA[1,2]-loaded PLGA microspheres as long-effective release system with high encapsulation efficiency","volume":"29","author":"Li","year":"2022","journal-title":"Drug Deliv."},{"key":"10.1016\/j.bcp.2026.118199_b0600","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3390\/md23040161","article-title":"Sustained release of \u03b1O-conotoxin GeXIVA[1,2] via hydrogel microneedle patch for chronic neuropathic pain management","volume":"23","author":"He","year":"2025","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.bcp.2026.118199_b0605","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114904","article-title":"Strategies for overcoming protein and peptide instability in biodegradable drug delivery systems","volume":"199","author":"Shi","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bcp.2026.118199_b0610","doi-asserted-by":"crossref","unstructured":"H. Ek, S. Ia, G. Ma, G. Vm, A. My, H. S, A. Ftt, T. T, Z. Gw, Differential regulation of cav 3.2 and cav 2.2 calcium channels by CB1 receptors and cannabidiol, Br. J. Pharmacol. 180 (2023). https:\/\/doi.org\/10.1111\/bph.16035.","DOI":"10.1111\/bph.16035"},{"key":"10.1016\/j.bcp.2026.118199_b0615","doi-asserted-by":"crossref","first-page":"7958","DOI":"10.1523\/JNEUROSCI.0247-14.2014","article-title":"Presynaptic calcium channel inhibition underlies CB1 cannabinoid receptor-mediated suppression of GABA release","volume":"34","author":"Szab\u00f3","year":"2014","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"10.1016\/j.bcp.2026.118199_b0620","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/s41467-024-46177-z","article-title":"Specific pharmacological and gi\/o protein responses of some native GPCRs in neurons","volume":"15","author":"Xu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118199_b0625","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10456-024-09963-3","article-title":"Neuropilin-1 controls vascular permeability through juxtacrine regulation of endothelial adherens junctions","volume":"28","author":"Pal","year":"2024","journal-title":"Angiogenesis"},{"key":"10.1016\/j.bcp.2026.118199_b0630","doi-asserted-by":"crossref","first-page":"675","DOI":"10.7150\/ijbs.79125","article-title":"Targeting vascular endothelial growth factor receptors as a therapeutic strategy for osteoarthritis and associated pain","volume":"19","author":"Ma","year":"2023","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.bcp.2026.118199_b0635","first-page":"320","article-title":"VEGF-A\/VEGFR-1 signalling and chemotherapy-induced neuropathic pain: therapeutic potential of a novel anti-VEGFR-1 monoclonal antibody","volume":"40","author":"Micheli","year":"2021","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"10.1016\/j.bcp.2026.118199_b0640","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.neuron.2025.01.005","article-title":"Divergent sex-specific pannexin-1 mechanisms in microglia and T cells underlie neuropathic pain","volume":"113","author":"Fan","year":"2025","journal-title":"Neuron"},{"key":"10.1016\/j.bcp.2026.118199_b0645","doi-asserted-by":"crossref","unstructured":"G. K, D. P, T. R, A. Hn, B. L, C.-R. A, L.-L. S, N. Ts, R. D, M. A, B. Nw, K. R, Neuropilin-1 is essential for vascular endothelial growth factor A-mediated increase of sensory neuron activity and development of pain-like behaviors, Pain 164 (2023). https:\/\/doi.org\/10.1097\/j.pain.0000000000002970.","DOI":"10.1097\/j.pain.0000000000002970"},{"key":"10.1016\/j.bcp.2026.118199_b0650","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1097\/j.pain.0000000000002850","article-title":"Targeting the vascular endothelial growth factor a\/neuropilin 1 axis for relief of neuropathic pain","volume":"164","author":"Stratton","year":"2023","journal-title":"Pain"},{"key":"10.1016\/j.bcp.2026.118199_b0655","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.03720","article-title":"Neuropilin-1 functions as a VEGFR2 co-receptor to guide developmental angiogenesis independent of ligand binding","volume":"3","author":"Gelfand","year":"2014","journal-title":"eLife"},{"key":"10.1016\/j.bcp.2026.118199_b0660","doi-asserted-by":"crossref","first-page":"421","DOI":"10.14245\/ns.2550462.231","article-title":"Advances in therapeutic applications of CRISPR genome editing for spinal pain management","volume":"22","author":"Kang","year":"2025","journal-title":"Neurospine"},{"key":"10.1016\/j.bcp.2026.118199_b0665","article-title":"The calcium channel terminator: hasta la vista pain","volume":"43","author":"Ek","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2026.118199_b0670","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cell.2020.03.023","article-title":"CRISPR-based therapeutic genome editing: strategies and in vivo delivery by AAV vectors","volume":"181","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2026.118199_b0675","article-title":"Beyond the promise: evaluating and mitigating off-target effects in CRISPR gene editing for safer therapeutics","volume":"11","author":"Lopes","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.bcp.2026.118199_b0680","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2118129119","article-title":"Targeted ubiquitination of sensory neuron calcium channels reduces the development of neuropathic pain","volume":"119","author":"Sun","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bcp.2026.118199_b0685","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.49253","article-title":"A potent voltage-gated calcium channel inhibitor engineered from a nanobody targeted to auxiliary CaV\u03b2 subunits","volume":"8","author":"Morgenstern","year":"2019","journal-title":"eLife"},{"key":"10.1016\/j.bcp.2026.118199_b0690","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1021\/acs.bioconjchem.9b00025","article-title":"Antibody delivery for intracellular targets: emergent therapeutic potential","volume":"30","author":"Singh","year":"2019","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.bcp.2026.118199_b0695","article-title":"Small molecule-mediated targeted protein degradation of voltage-gated sodium channels involved in pain","author":"Chamessian","year":"2025","journal-title":"BioRxiv Prepr. Serv. Biol."},{"key":"10.1016\/j.bcp.2026.118199_b0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmr.2025.100090","article-title":"Recent advances in the pharmacology of voltage-gated ion channels","volume":"77","author":"Lopez-Mateos","year":"2025","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bcp.2026.118199_bib709","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0140-6736(94)90820-6","article-title":"Gabapentin","volume":"343","author":"Chadwick","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2026.118199_bib710","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrd1756","article-title":"Pregabalin","volume":"4","author":"Dworkin","year":"2005","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226005381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226005381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:13:52Z","timestamp":1786652032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226005381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":142,"alternative-id":["S0006295226005381"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118199","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting Cav2.2 channels for pain management: challenges, innovations, and future perspectives","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118199","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"118199"}}